Canadian company develops nose-to-brain technology for fast-acting cannabinoid treatments.

Screen Shot 2019-07-25 at 9.54.25 AM.png


According to Proactive Investors, the Canadian company PreveCeutical Medical has developed a sustained-release CBD formulation of their Sol-gel pain-relief technology. These easy-to-use treatments release cannabinoids into the central nervous system through nasal mucosal tissue.

While the Sol-gel drug delivery and research program is still in the final stages of testing, PreveCeutical has already begun a new search for new therapeutic products such as non-addictive analgesic peptides to treat athletes who are suffering from concussions.